MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Sareban et al. explored expert perspectives on establishing a reimbursement framework for digital therapeutics (DTx) in Austria. Through seven semi-structured interviews with Austrian healthcare stakeholders, the authors identified critical factors necessary for a viable national reimbursement strategy. These include user and prescriber acceptance of DTx, robust clinical evidence, data security aligned with European standards, and clear economic evaluation.

Between late February 2024 and early March 2025, seven more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 59 health apps are currently available in the DiGA Directory, and ten health apps were delisted from the Directory.

MTRC, a Pan-European Med Tech market access consultancy, is opening a position of junior Research Fellow to contribute to our evidence synthesis projects, including systematic reviews and value dossiers, in the evolving field of medical devices. Work is purely analytical, no hands-on/clinical/lab work is involved.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 10th of March, we plan to work on 21 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Urbina et al. analyzed the EUnetHTA 21 project, a European initiative designed to support the implementation of Regulation (EU) 2021/2282 on Health Technology Assessment (HTA). Conducted by 13 European HTA bodies, the project resulted in 20 guidance documents, 13 templates, and pilot Joint Clinical Assessments (JCAs) aimed at refining evaluation methods. The study highlights the importance of structured collaboration and regulatory preparedness, providing a roadmap for the future integration of HTA at the EU level.

In February 2025, the HTA body of Tuscany Regional Healthcare published four new rapid HTA reports on medical devices used in cardiovascular, endoscopy, pulmonology, and general surgical fields.

MTRC announces the start of the new service - Analysis of Tender Requirements for Medical Devices. Our team thoroughly reviews the criteria that procurement bodies use to evaluate bids. We break down how factors like price, quality, clinical and economic evidence, and sustainability influence decision-making. With these insights, we guide you in aligning your product’s unique strengths to the specific expectations of different European markets.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-Based Publications Digest. In a recent publication, Chu et al. conducted a systematic review to develop an admission criterion framework for high-cost medical consumables in governmental hospitals. The study was carried out in a multi-country context and established a framework with seven first-level and 23 second-level indicators, highlighting the primacy of “Clinical Benefit,” followed by “Economic Value,” and “Organizational Impact.” This framework helps decision-makers ensure both efficient resource allocation and robust clinical outcomes.

On February 18, 2025, the Swiss Health Observatory (Obsan) published its 2023 report confirming the ongoing shift from inpatient to outpatient care in Switzerland. The number of procedures required to be performed in outpatient settings to be reimbursed expanded from six in 2019 to 18 in 2023, with outpatient costs two to eight times lower. Despite the shift, overall healthcare costs have risen due to an increase in treatment volumes.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Cimprich et al. discussed strategies of regulatory actors, particularly market authorization agencies, health technology assessment agencies, and health care procurement agencies, for integrating environmental sustainability requirements into the regulation of medicines and medical devices. Their analysis, contextualized within diverse healthcare settings, reveals significant untapped possibilities for strengthening regulatory frameworks to mitigate the ecological footprint of health technologies.

On February 17, 2025, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 200 and 096 with changes to be implemented no later than March 10, 2025. Thirty-five new procedure codes related to cardiovascular, gastrointestinal, nephrology, peripheral vascular, and general surgery areas and ten new diagnostic codes concerning in-vitro diagnostics, endoscopy, and pulmonology were introduced.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van den Broek-Altenburg et al. reviewed 20–25 years of economic value assessment approaches in healthcare, highlighting the growing focus on individual preferences over broad societal metrics in value-based care models. The study underscores the complexities of incorporating patient-specific preferences into economic evaluations, and addresses recognized limitations of QALY measures. The authors discussed emerging alternative valuation frameworks that could influence future policy and reimbursement decision-making.